MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definit...
Funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™ Funding round led by Mercia C...
Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the m...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precis...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint resea...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
"We are very pleased about the cooperation with Novaliq, a pioneer for groundbreaking non-aqueous eye drop technology. With regard to the unique properties...
SomaLogic, Inc., a leader in proteomics technology, announced today their collaboration with Citogen, the Longwood Group’s customer services and supp...
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product bios...
In this collaboration, Iktos’ de novo generative design technology in combination with Curreio’s state-of-the-art cryo-EM platform will be used...
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable li...
Gives Nordic Nanovector access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-b...
© 2025 Biopharma Boardroom. All Rights Reserved.
